Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

High Body Mass Index (BMI) in North American Elderly Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Rituximab (R)-CHOP Compensates for Negative Impact of Male Gender

Zheng Zhou, MD PhD, Alfred W. Rademaker, PhD, Leo I. Gordon, MD, Ann S. LaCasce, MD, Allison Crosby-Thompson, Ann Vanderplas, MS, Gregory A Abel, MD MPH, Maria A. Rodriguez, MD, Auayporn Nademanee, MD, Mark Kaminski, Myron S. Czuczman, MD, Michael M. Millenson, MD, Joyce Niland, PhD, Andrew D. Zelenetz, MD PhD, Jonathan W. Friedberg, MD, Jane N. Winter, MD

Blood (2014) 124 (21): 3046.

https://doi.org/10.1182/blood.V124.21.3046.3046

Published: 2014

Journal Articles

Antibiotic Therapy of H. Pylori Negative Gastric MALT Lymphoma

Seung Tae Lee, MD PhD, Purnima Teegavarupu, MD, Anusha Karri, Saswatha Anireddy, Fredrick B. Hagemeister, MD, Jorge E. Romaguera, MD, Luis Fayad, MD, Maria A. Rodriguez, MD, Felipe Samaniego, MD, Nathan Fowler, MD, Yasuhiro Oki, MD, Francesco Turturro, MD, Jason R. Westin, MD, Larry W Kwak, MD PhD, Bouthaina S. Dabaja, MD, Lei Feng, MS, R Eric Davis, MD, Sattva S Neelapu, MD

Blood (2014) 124 (21): 1735.

https://doi.org/10.1182/blood.V124.21.1735.1735

Published: 2014

Journal Articles

Comparison of Referring and Final Pathology for T-Cell Lymphomas in the NCCN

Alex F Herrera, MD, Allison Crosby-Thompson, Jonathan W. Friedberg, MD, Gregory A. Abel, MD, MPH, Myron S. Czuczman, MD, Leo I. Gordon, MD, Mark S. Kaminski, MD, Michael Millenson, MD, Auayporn Nademanee, MD, Joyce Niland, PhD, Maria A. Rodriguez, MD, Andrew D. Zelenetz, MD, PhD, Ann S. LaCasce, MD

Blood (2012) 120 (21): 1610.

https://doi.org/10.1182/blood.V120.21.1610.1610

Published: 2012

Journal Articles

R-HCVAD Alternating with R-Methotrexate Cytarabine in Younger Patients (pts) with IH and High-Risk Age Adjusted-IPI DLBCL

Yasuhiro Oki, MD, Jason R. Westin, MD, Nathan Fowler, MD, Sattva Neelapu, MD, F.B. Hagemeister, MD, Peter McLaughlin, MD, Larry W. Kwak, MD, PhD, Jorge Enrique Romaguera, Michelle Fanale, MD, Anas Younes, MD, Maria A. Rodriguez, MD, Robert Z. Orlowski, MD, PhD, Michael Wang, M.D., Souzanne T Ouzounian, Felipe Samaniego, M.D., Luis Fayad, MD

Blood (2012) 120 (21): 3707.

https://doi.org/10.1182/blood.V120.21.3707.3707

Published: 2012

Journal Articles

An Enhanced International Prognostic Index (IPI) for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab Era Using the National Comprehensive Cancer Network (NCCN) Database.

Zheng Zhou, MD, PhD, Alfred W. Rademaker, PhD, Leo I. Gordon, MD, Ann S. LaCasce, MD, Ann Vanderplas, MS, Allison Crosby-Thompson, Andrew D Zelenetz, MD, PhD, Gregory A. Abel, MD, MPH, Maria A. Rodriguez, MD, Auayporn Nademanee, MD, Mark S. Kaminski, MD, Myron S. Czuczman, MD, Michael Millenson, MD, Joyce Niland, PhD, Jonathan W. Friedberg, MD, Jane N. Winter, MD

Blood (2012) 120 (21): 2656.

https://doi.org/10.1182/blood.V120.21.2656.2656

Published: 2012

Journal Articles

Natural History of Transformed Non-Hodgkin Lymphoma in the Rituximab Era: Analysis of the National Comprehensive Cancer Network (NCCN) NHL Outcomes Database.

Makiko Ban-Hoefen, MD, Ann Vanderplas, MS, Jennifer L. Kelly, PhD, MPH, Allison Crosby-Thompson, Gregory A. Abel, MD, MPH, Myron S. Czuczman, MD, Leo I. Gordon, MD, Mark S. Kaminski, MD, Michael Millenson, MD, Auayporn Nademanee, MD, Maria A. Rodriguez, MD, Andrew D. Zelenetz, MD, PhD, Joyce Niland, PhD, Ann LaCasce, MD, Jonathan W. Friedberg, MD

Blood (2012) 120 (21): 2669.

https://doi.org/10.1182/blood.V120.21.2669.2669

Published: 2012

Journal Articles

Continuous Decline in Second Malignancy Occurrence in Patients with Hodgkin Lymphoma; Analysis of 1670 Patients Over the Past 5 Decades

Bouthaina S. Dabaja, MD, Ferial Shihadeh, MD, Carol Etzel, PhD, Liang Fu-wen, MS, Shervin Mohajer Shirvani, MD, Leslie Ballas, MD, Pamela Allen, PhD, Maria A. Rodriguez, MD, Michelle A. Fanale, MD, Anas Younes, MD

Blood (2011) 118 (21): 2694.

https://doi.org/10.1182/blood.V118.21.2694.2694

Published: 2011

Journal Articles

Clinical Implications of PET-Negative Residual Disease At the Completion of Chemotherapy for Diffuse Large B-Cell Lymphoma

Bouthaina S. Dabaja, MD, Jack Phan, MD PhD, L. Jeffrey Medeiros, MD, F.B. Hagemeister, MD, Hubert Chuang, MD, Luis Fayad, MD, Ferial Shihadeh, MD, Pamela Allen, PhD, Christine Wogan, MS, Maria A. Rodriguez, MD

Blood (2011) 118 (21): 2695.

https://doi.org/10.1182/blood.V118.21.2695.2695

Published: 2011

Journal Articles

Phase II Study with R-FND Followed by 90-Y Ibritumomab Tiuxetan Radioimmunotherapy and Rituximab Maintenance for Untreated High-Risk Follicular Lymphoma

Nathan H. Fowler, MD, Sattva S. Neelapu, MD, Michelle A. Fanale, MD, Maria A. Rodriguez, MD, Barbara Pro, MD, F.B. Hagemeister, MD, Anas Younes, MD, Jatin J Shah, MD, Larry W Kwak, MD, PhD, Diana Rodriguez, Peter McLaughlin, MD

Blood (2011) 118 (21): 99.

https://doi.org/10.1182/blood.V118.21.99.99

Published: 2011

Journal Articles

Outcomes with Autologous (Auto) and Allogeneic (Allo) Stem Cell Transplantation (SCT) for Relapsed/Refractory Follicular Lymphoma (FL) in the Post-Rituximab Era: A Comparative Analysis From the National Comprehensive Cancer Network (NCCN) Non-Hodgkin's Lymphoma (NHL) Outcomes Database Project,

Andrew M. Evens, DO, MSc, Ann Vanderplas, M.S., Ann LaCasce, MD, MSc, Allison Crosby, MS, Auayporn Nademanee, M.D., Mark S. Kaminski, MD, Gregory A. Abel, MD, MPH, Michael Millenson, MD, Myron S. Czuczman, MD, Maria A. Rodriguez, MD, Joyce Niland, PhD, Andrew D Zelenetz, MD, PhD, Leo I. Gordon, MD, FACP, Jonathan Friedberg, MD

Blood (2011) 118 (21): 4112.

https://doi.org/10.1182/blood.V118.21.4112.4112

Published: 2011

Journal Articles

Incidence, Method and Covariates of Central Nervous System (CNS) Prophylaxis for Diffuse Large B-Cell Lymphoma In the National Comprehensive Cancer Network (NCCN) Lymphoma Database

Anita Kumar, MD, Ann Vanderplas, Ann S. LaCasce, MD, MSc, Maria A. Rodriguez, MD, Allison L. Crosby, MS, Eva Lepisto, MSc, MA, Myron S. Czuczman, MD, Auayporn Nademanee, M.D., Joyce Niland, PhD, Leo I. Gordon, MD, FACP, Michael Millenson, MD, Andrew D. Zelenetz, MD, PhD, Jonathan W. Friedberg, MD, Gregory A. Abel, MD, MPH

Blood (2010) 116 (21): 1756.

https://doi.org/10.1182/blood.V116.21.1756.1756

Published: 2010

Journal Articles

Patterns of Use of FDG-PET for the Initial Staging of Follicular Lymphoma (FL) and Its Impact on Initial Treatment Strategy and Outcomes In the National Comprehensive Cancer Network (NCCN) Lymphoma Database

Karim E Abou-Nassar, MD, Ann Vanderplas, Jonathan W. Friedberg, MD, Gregory Abel, MD, MPH, Joyce Niland, PhD, Maria A. Rodriguez, MD, Myron S. Czuczman, MD, Michael Millenson, MD, Allison Crosby, MS, Leo I Gordon, MD, FACP, Andrew D Zelenetz, MD, Ann LaCasce, MD, MSc

Blood (2010) 116 (21): 81.

https://doi.org/10.1182/blood.V116.21.81.81

Published: 2010

Journal Articles

Variations in Surveillance Imaging for Patients with Treated Diffuse Large B-Cell Lymphoma in the National Comprehensive Cancer Network (NCCN) Lymphoma Database.

Gregory A. Abel, MD, MPH, Ann Vanderplas, MS, Jonathan W. Friedberg, MD, Joyce Niland, PhD, Maria A. Rodriguez, MD, Myron S Czuczman, MD, Michael Millenson, MD, Allison L. Crosby, Leo I. Gordon, MD, Douglas W. Blayney, MD, Andrew D. Zelenetz, MD, PhD, Ann S. LaCasce, MD

Blood (2009) 114 (22): 1387.

https://doi.org/10.1182/blood.V114.22.1387.1387

Published: 2009

Journal Articles

R-CHOP, Followed by High Dose Therapy and Autologous Stem Cell Rescue (HDT/ASCR), and R-Hypercvad Have Equivalent Progression-Free Survival and Are Superior to R-CHOP Alone in Younger Patients with Mantle Cell Lymphoma: a Comparative Effectiveness Analysis From the National Comprehensive Cancer Network (NCCN) Non-Hodgkin's Lymphoma Outcomes Database Project.

Ann LaCasce, MD, Jonathan L. Vandergrift, MS, Maria A. Rodriguez, MD, Allison L. Crosby, MS, Eva M. Lepisto, MSc, MA, Myron S. Czuczman, MD, Auayporn P. Nademanee, MD, Douglas W. Blayney, MD, Leo I. Gordon, MD, Michael Millenson, MD, Ann Vanderplas, Gregory A. Abel, MD, MPH, Andrew D. Zelenetz, MD, PhD, Jonathan W. Friedberg, MD

Blood (2009) 114 (22): 403.

https://doi.org/10.1182/blood.V114.22.403.403

Published: 2009

Journal Articles

Rituximab + ABVD Improves Event-Free Survival (EFS) in Patients with Classical Hodgkin Lymphoma in All International Prognostic Score (IPS) Groups and in Patients Who Have PET Positive Disease after 2–3 Cycles of Therapy.

Amanda R. Wedgwood, MSN, Michelle A. Fanale, MD, Luis E. Fayad, MD, Peter McLaughlin, MD, Fredrick B. Hagemeister, MD, Barbara Pro, MD, Jorge Romaguera, MD, Maria A. Rodriguez, MD, Felipe Samaniego, MD, Anas Younes, MD

Blood (2007) 110 (11): 215.

https://doi.org/10.1182/blood.V110.11.215.215

Published: 2007

Journal Articles

R-HCVAD/R-MTX-ARAC Is an Effective Regimen for Untreated Diffuse Large B-Cell Lymphoma (DLBCL) with Aggressive Features in Patients Younger Than 60 Years

Luis Fayad, MD, Barbara Pro, MD, Fredrick Hagemeister, MD, Fernando Cabanillas, MD, Felipe Samaniego, MD, Peter McLaughlin, MD, Michael Wang, MD, Sattva Neelapu, MD, Larry Kwak, MD, PhD, Jorge Romaguera, MD, Maria A. Rodriguez, MD

Blood (2007) 110 (11): 1285.

https://doi.org/10.1182/blood.V110.11.1285.1285

Published: 2007

Journal Articles

The Addition of Rituximab to CHOP Chemotherapy Improves Response Rate, Failure-Free Survival and Overall Survival for Follicular Grade 3 Lymphoma Compared to CHOP Alone

Michael J. Overman, MD, Lei Feng, MS, Barbara Pro, MD, Peter McLaughlin, MD, Mark Hess, BBA, Felipe Samaniego, MD, Anas Younes, MD, Jorge E. Romaguera, MD, Frederick B. Hagemeister, MD, Larry Kwak, MD, PhD, Fernando Cabanillas, MD, Maria A. Rodriguez, MD, Luis E. Fayad, MD

Blood (2007) 110 (11): 1289.

https://doi.org/10.1182/blood.V110.11.1289.1289

Published: 2007

Journal Articles

Achievement of FDG-PET Negativity Does Not Predict Durable Responses in T-Cell Lymphoma.

Barbara Pro, MD, Rodolfo F. Nunez, MD, Jorge Romaguera, MD, Maria A. Rodriguez, MD, Fredrick Hagemeister, MD, Luis Fayad, MD

Blood (2006) 108 (11): 2404.

https://doi.org/10.1182/blood.V108.11.2404.2404

Published: 2006

Journal Articles

Activity of Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin ® ) in 22 Patients with Relapsed and Refractory Mantle Cell Lymphoma (MCL).

Anas Younes, MD, Barbara Pro, MD, Maria A. Rodriguez, MD, Jorge E. Romaguera, MD, Peter McLaughlin, MD, Michael Wang, MD, Fredrick B. Hagemeister, MD, Nam H. Dang, MD, Sattva Neelapu, MD, Donald Podoloff, MD

Blood (2005) 106 (11): 2452.

https://doi.org/10.1182/blood.V106.11.2452.2452

Published: 2005

Journal Articles

Interim Analysis of a Phase II Study of the Combination of Denileukin Diftitox (Ontak) and Rituximab for Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma.

Nam H. Dang, MD, PhD, Peter McLaughlin, MD, Luis Fayad, MD, Jorge Romaguera, MD, Fredrick Hagemeister, MD, Anas Younes, MD, Sattva Neelapu, MD, Felipe Samaniego, MD, Dan Jones, MD, PhD, Pamela L. Walker, RN, Maria A. Rodriguez, MD, Larry Kwak, MD, PhD, Barbara Pro, MD

Blood (2005) 106 (11): 3349.

https://doi.org/10.1182/blood.V106.11.3349.3349

Published: 2005

NARROW

High Body Mass Index (BMI) in North American Elderly Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Rituximab (R)-CHOP Compensates for Negative Impact of Male Gender

Antibiotic Therapy of H. Pylori Negative Gastric MALT Lymphoma

Comparison of Referring and Final Pathology for T-Cell Lymphomas in the NCCN

R-HCVAD Alternating with R-Methotrexate Cytarabine in Younger Patients (pts) with IH and High-Risk Age Adjusted-IPI DLBCL

An Enhanced International Prognostic Index (IPI) for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab Era Using the National Comprehensive Cancer Network (NCCN) Database.

Natural History of Transformed Non-Hodgkin Lymphoma in the Rituximab Era: Analysis of the National Comprehensive Cancer Network (NCCN) NHL Outcomes Database.

Continuous Decline in Second Malignancy Occurrence in Patients with Hodgkin Lymphoma; Analysis of 1670 Patients Over the Past 5 Decades

Clinical Implications of PET-Negative Residual Disease At the Completion of Chemotherapy for Diffuse Large B-Cell Lymphoma

Phase II Study with R-FND Followed by 90-Y Ibritumomab Tiuxetan Radioimmunotherapy and Rituximab Maintenance for Untreated High-Risk Follicular Lymphoma

Outcomes with Autologous (Auto) and Allogeneic (Allo) Stem Cell Transplantation (SCT) for Relapsed/Refractory Follicular Lymphoma (FL) in the Post-Rituximab Era: A Comparative Analysis From the National Comprehensive Cancer Network (NCCN) Non-Hodgkin's Lymphoma (NHL) Outcomes Database Project,

Incidence, Method and Covariates of Central Nervous System (CNS) Prophylaxis for Diffuse Large B-Cell Lymphoma In the National Comprehensive Cancer Network (NCCN) Lymphoma Database

Patterns of Use of FDG-PET for the Initial Staging of Follicular Lymphoma (FL) and Its Impact on Initial Treatment Strategy and Outcomes In the National Comprehensive Cancer Network (NCCN) Lymphoma Database

Variations in Surveillance Imaging for Patients with Treated Diffuse Large B-Cell Lymphoma in the National Comprehensive Cancer Network (NCCN) Lymphoma Database.

Rituximab + ABVD Improves Event-Free Survival (EFS) in Patients with Classical Hodgkin Lymphoma in All International Prognostic Score (IPS) Groups and in Patients Who Have PET Positive Disease after 2–3 Cycles of Therapy.

R-HCVAD/R-MTX-ARAC Is an Effective Regimen for Untreated Diffuse Large B-Cell Lymphoma (DLBCL) with Aggressive Features in Patients Younger Than 60 Years

The Addition of Rituximab to CHOP Chemotherapy Improves Response Rate, Failure-Free Survival and Overall Survival for Follicular Grade 3 Lymphoma Compared to CHOP Alone

Achievement of FDG-PET Negativity Does Not Predict Durable Responses in T-Cell Lymphoma.

Activity of Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin ® ) in 22 Patients with Relapsed and Refractory Mantle Cell Lymphoma (MCL).

Interim Analysis of a Phase II Study of the Combination of Denileukin Diftitox (Ontak) and Rituximab for Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only